AREVA Med et RadioMedix unissent leurs forces pour développer de nouveaux traitements contre les tumeurs neuroendocrines

Houston, Texas, et Bethesda, Maryland, le 18 mai 2015

RadioMedix, a clinical phase biotechnology company focused in the development of  radiopharmaceuticals for targeted diagnosis and therapy of cancer, and AREVA Med, the AREVA medical subsidiary developing innovative therapies to fight cancer, announced today that they have entered into an agreement to co-develop a novel treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212.


Under the terms of the agreement, RadioMedix and AREVA Med will assess the efficacy of combining somatostatin analogs’ neuroendocrine tumor targeting capabilities with the cell-killing potential of AREVA Med’s lead-212 radionuclide. This approach, known as “Peptide Receptor Radio Therapy” (PRRT), has already been tested with beta emitting radioisotopes.  The alpha emitters from lead-212’s decay chain are expected to deliver superior clinical benefits to patients suffering from metastasized NETs where conventional methods, such as surgery or chemotherapy, have been ineffective.


Development of the next generation of PRRT agents with Alpha emitters for targeted treatment of metastatic or inoperable neuroendocrine cancers is a natural next step in evolution of this treatment platform.  Alpha PRRT will bring us closer to a “cure” of this cancer and will provide significant new hope to our patients fighting this disease. Collaboration with AREVA Med will allow us to have a sustainable source of Alpha emitter 212Pb to achieve this goal” said Ebrahim S. Delpassand, M.D. RadioMedix Chairman and CEO.


This partnership will combine RadioMedix’s expertise and assets in the development of NET diagnostic and treatments solutions and conducting clinical trials with AREVA Med’s know-how in extracting, purifying, and delivering lead-212 for therapeutic applications as well as the expertise of Macrocyclics (AREVA Med’s Texas-based affiliate) in designing and producing the targeting peptide.


Patrick Bourdet, CEO of AREVA Med, said: “Now that AREVA Med has established sustainable 212Pb production capacities, we are entering into a new stage of our development focused on expanding our targeted alpha therapy pipeline. In this promising context, we are delighted to partner with RadioMedix, as our complementary competencies and expertise will undoubtedly serve our common goals”.
En poursuivant votre navigation, vous acceptez l'utilisation des cookies. Pour plus d’informations, gérer ou modifier les paramètres des cookies sur votre ordinateur, lisez notre Politique Cookies dans nos mentions légales
J'accepte les cookies